ACADIA Pharmaceuticals Inc. (ACAD) announced Thursday morning that the FDA has agreed that the data from the Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing of a New Drug Application for the treatment of Parkinson's disease psychosis. ACADIA will no longer conduct the Phase III -021 study that was planned as a confirmatory trial.
ACADIA Pharmaceuticals has gapped open sharply higher Thursday and is now up 3.47 at $11.44 on above average volume. The stock has jumped to a new high for the year.
For comments and feedback: editorial@rttnews.com